We are live on
!
Find out more
BCM
Burrage Capital Management Portfolio holdings
AUM
$99.7M
1-Year Est. Return
66.05%
This Fund
S&P 500
This Quarter
Est. Return
+28.68%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$131M
AUM Growth
+$4.53M
(+3.6%)
Cap. Flow
-$13.5M
Cap. Flow
% of AUM
-10.25%
Top 10 Holdings %
Top 10 Hldgs %
64.4%
Holding
34
New
7
Increased
2
Reduced
15
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Protalix BioTherapeutics
PLX
|
+$8.85M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$5.7M |
| 3 |
INZY
Inozyme Pharma
INZY
|
+$4.07M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
+$3.18M |
| 5 |
Intellia Therapeutics
NTLA
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AIMT
Aimmune Therapeutics
AIMT
|
+$11.5M |
| 2 |
OrthoPediatrics
KIDS
|
+$7.88M |
| 3 |
AnaptysBio
ANAB
|
+$4.88M |
| 4 |
Assembly Biosciences
ASMB
|
+$3.29M |
| 5 |
Regenxbio
RGNX
|
+$3.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EPZM
1
DELISTED
Epizyme, Inc
EPZM
| $10.1M | 7.7% |
930,467
-72,061
| -7% | -$889K |
|
2
PTC Therapeutics
PTCT
$6.52B
| $9.83M | 7.49% |
161,083
-12,462
| -7% | -$734K |
|
3
NeoGenomics
NEO
$1.9B
| $9.63M | 7.34% |
178,777
-13,894
| -7% | -$628K |
|
|
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.59M | 7.31% |
1,388,136
-107,379
| -7% | -$687K |
|
|
5
Protalix BioTherapeutics
PLX
$192M
| $8.97M | 6.83% |
+2,470,332
| New | +$8.85M |
|
|
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $8.83M | 6.73% |
72,484
-5,634
| -7% | -$617K |
|
|
LITS
7
Lite Strategy Inc
LITS
$33.6M
| $8.46M | 6.45% |
160,297
+8,345
| +5% | +$481K |
|
|
8
BioCryst Pharmaceuticals
BCRX
$2.36B
| $8.24M | 6.28% |
+1,105,673
| New | +$5.7M |
|
|
YMAB
9
DELISTED
Y-mAbs Therapeutics
YMAB
| $5.69M | 4.34% |
114,962
-8,063
| -7% | -$373K |
|
10
Insmed
INSM
$23.5B
| $5.14M | 3.92% |
154,562
-10,838
| -7% | -$396K |
|
11
Cytokinetics
CYTK
$10.9B
| $5.11M | 3.9% |
246,036
-18,823
| -7% | -$344K |
|
|
APLS
12
DELISTED
Apellis Pharmaceuticals
APLS
| $4.65M | 3.55% |
81,357
+4,553
| +6% | +$193K |
|
13
Aurinia Pharmaceuticals
AUPH
$2.05B
| $4.65M | 3.55% |
336,384
-25,999
| -7% | -$378K |
|
14
Korro Bio
KRRO
$177M
| $4.39M | 3.35% |
2,493
-190
| -7% | -$251K |
|
15
ADC Therapeutics
ADCT
$172M
| $4.03M | 3.07% |
125,850
-9,062
| -7% | -$297K |
|
|
INZY
16
DELISTED
Inozyme Pharma
INZY
| $3.52M | 2.69% |
+170,796
| New | +$4.07M |
|
|
17
Intellia Therapeutics
NTLA
$1.59B
| $3.49M | 2.66% |
+64,079
| New | +$2.33M |
|
18
Fulcrum Therapeutics
FULC
$243M
| $3.18M | 2.43% |
271,926
-19,719
| -7% | -$223K |
|
19
Crinetics Pharmaceuticals
CRNX
$8.88B
| $3.16M | 2.41% |
224,129
-17,149
| -7% | -$239K |
|
|
20
Mirum Pharmaceuticals
MIRM
$7.25B
| $2.82M | 2.15% |
+161,628
| New | +$3.18M |
|
|
MRUS
21
DELISTED
Merus
MRUS
| $2.29M | 1.75% |
130,683
-9,493
| -7% | -$140K |
|
|
GTHX
22
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $2.12M | 1.61% |
117,708
-110,889
| -49% | -$1.66M |
|
|
TECX
23
Tectonic Therapeutic
TECX
$615M
| $2.03M | 1.55% |
+12,143
| New | +$2.16M |
|
24
Black Diamond Therapeutics
BDTX
$103M
| $1.12M | 0.85% |
+34,891
| New | +$1.15M |
|
|
AUTL
25
Autolus Therapeutics
AUTL
$383M
| $134K | 0.1% |
15,006
| – | – |
|
Similar funds
WCM
CCM
RGM
TCM
RC
AC
QVT
WFWM
Burrage Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Burrage Capital Management held 34 positions worth $131M, up 3.6% from $127M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Burrage Capital Management withdrew a net $13.5M in Q4 2020, closing 9 positions and reducing 15 holdings. Its most notable exit was Aimmune Therapeutics, an estimated $11.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier.
Against the trend, Burrage Capital Management opened a new position in Protalix BioTherapeutics worth $8.97M.
- Burrage Capital Management's largest Q4 2020 buy was Protalix BioTherapeutics: 2,470,332 shares worth $8.97M.
- Burrage Capital Management added most to Lite Strategy Inc in Q4 2020, an estimated $481K increase.
- Burrage Capital Management's biggest Q4 2020 reduction was G1 Therapeutics, Inc. Common Stock, cutting an estimated $1.66M.
- Burrage Capital Management fully exited Aimmune Therapeutics in Q4 2020, selling an estimated $11.5M.
- Burrage Capital Management's ten largest holdings make up 64% of its $131M portfolio in Q4 2020.
- Burrage Capital Management opened 7 new positions and closed 9 in Q4 2020.
- Burrage Capital Management's portfolio value rose 3.6% quarter-over-quarter to $131M.
Based on Burrage Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.